Skip to main content
OpenTrials

Clinical trial condition

Gram-Negative Bacterial Infections

Explore clinical trials studying Gram-Negative Bacterial Infections. Study availability and eligibility vary by location and protocol.

1,462 public trials 132 recruiting studies
Refine in advanced search Browse all conditions

Gram-Negative Bacterial Infections trial results

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +12 more
Locations
  • GSK Investigational Site Benton, Arkansas, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Antioch, California, United States
  • GSK Investigational Site Fremont, California, United States
View all 14 locations
View Trial Details
Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Benton, Arkansas, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Antioch, California, United States
View all 19 locations
View Trial Details
Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

NCT01900899

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Espoo Vaccine Research Clinic Espoo, Finland
  • Tampereen yliopisto/ Etela-Helsingin rokotetutkimusklinikka Helsinki, Finland
  • Helsinki East Vaccine Research Clinic Helsinki, Finland
  • Tampereen Yliopisto/ Jarvenpaan rokotetutkimusklinikka Jarvenpaa, Finland
View Trial Details
Completed

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

NCT01682876

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Sacramento, California, United States
  • GSK Investigational Site Lake Mary, Florida, United States
  • GSK Investigational Site Marietta, Georgia, United States
View all 19 locations
View Trial Details
Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

NCT01962207

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Espoo Vaccine Research Clinic Espoo, Finland
  • South Helsinki Vaccine Research Clinic Helsinki, Finland
  • Helsinki East Vaccine Research Clinic Helsinki, Finland
  • Jarvenpaa Vaccine Research Clinic Jarvenpaa, Finland
View Trial Details

Related conditions